Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 17,001 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ELEVATE Clear all
Completed Not applicable Interventional

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05663463
View directory record Official record
Conditions
Solid Organ Transplant
Interventions
Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 24, 2026, 6:23 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

NCT05163314
View directory record Official record
Conditions
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 56 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 24, 2026, 6:23 AM EDT
Terminated Early Phase 1 Interventional

HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

NCT05006040
View directory record Official record
Conditions
High Risk Acute Lymphoblastic Leukemia
Interventions
Hybrid Closed Loop System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

YMCA Exercise Intervention for Smoking Cessation Study

NCT03080090
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Aerobic exercise, Smoking Cessation Intervention
Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

NCT00563797
View directory record Official record
Conditions
Alcohol Dependence, Depression
Interventions
Mecamylamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 24, 2026, 6:23 AM EDT
Completed No phase listed Observational

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

NCT00033397
View directory record Official record
Conditions
Breast Cancer
Interventions
biopsy, magnetic resonance imaging, radiomammography, ultrasound imaging, gadopentetate dimeglumine, chemotherapy
Procedure · Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Fluorescence-guided Surgery for Low- and High-grade Gliomas

NCT01502280
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevulinic acid (ALA), Placebo - ascorbic acid
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee

NCT02326961
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celution Device, Placebo
Device · Other
Lead sponsor
Cytori Therapeutics
Industry
Eligibility
40 Years to 69 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Mesa, Arizona • Little Rock, Arkansas • La Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 24, 2026, 6:23 AM EDT
Terminated Not applicable Interventional

A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension

NCT02895386
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
ROX Coupler, Sham procedure
Device · Other
Lead sponsor
ROX Medical, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 24, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Treatment of Elevated Blood Pressures in Early Pregnancy

NCT05955040
View directory record Official record
Conditions
Elevated Blood Pressure, Pregnancy Induced Hypertension
Interventions
Nifedipine, Labetalol
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia

NCT00003659
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, rituximab, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Not applicable Interventional

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

NCT00296023
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 24, 2026, 6:23 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

High-Resolution Measurements of Diet-Microbiome Interactions

NCT07856823
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome)
Interventions
Inulin, Low-fiber control breakfast shake, Atmo Gas-Sensing Capsule, CapScan Regional Fluid-Sampling Capsule
Dietary Supplement · Other · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00101296
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
tipifarnib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 24, 2026, 6:23 AM EDT
Active, not recruiting Phase 1 Interventional

Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer

NCT04311762
View directory record Official record
Conditions
Lung Cancer Metastatic
Interventions
cisplatin
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 24, 2026, 6:23 AM EDT
Recruiting No phase listed Observational

Prospective Validation of a Points Score System Predicting 30-day Survival

NCT05100342
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Point score prediction tool for 30-day survival
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Avon, Indiana • Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 24, 2026, 6:23 AM EDT
Active, not recruiting Phase 2 Interventional

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373
View directory record Official record
Conditions
Neuroblastoma
Interventions
GM-CSF + Naxitamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Not applicable Interventional Results available

Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography

NCT01434641
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
low-dose stress MPI SPECT
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 24, 2026, 6:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School

NCT04478240
View directory record Official record
Conditions
Substance Use, Stress, Relation, Interpersonal, Bullying, Victimisation, Mental Health Issue, Sleep, Inadequate, Social Skills
Interventions
PeerLearning.net
Behavioral
Lead sponsor
Oregon Research Behavioral Intervention Strategies, Inc.
Industry
Eligibility
Not listed
Enrollment
924 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 24, 2026, 6:23 AM EDT
Completed No phase listed Observational

Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate

NCT01319591
View directory record Official record
Conditions
CNS Lymphoma, CNS Involvement of Systemic Lymphoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 24, 2026, 6:23 AM EDT
Recruiting Not applicable Interventional

FEED-Cystic Fibrosis (FEED-CF)

NCT05766774
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Low-added sugar, high-fat diet, High-added sugar, high-fat CF diet
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 6:23 AM EDT